Literature DB >> 9705178

Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.

J C Schmit1, L Ruiz, L Stuyver, K Van Laethem, I Vanderlinden, T Puig, R Rossau, J Desmyter, E De Clercq, B Clotet, A M Vandamme.   

Abstract

The performance to detect drug resistance mutations in the reverse transcriptase gene of HIV-1 was compared for direct solid phase sequencing, selective polymerase chain reaction (PCR) using the amplification refractory mutation system (ARMS) and the new line probe assay (LIPA) HIV-1 RT. The three tests were undertaken on 50 plasma samples from 25 treatment-experienced patients under combination therapy with dideoxynucleoside analogues. LiPA HIV-1 RT gave interpretable results in 80 to 96% of the samples depending on the codon of interest. In 2% of the samples a failure to amplify resulted in uninterpretable results for sequencing. ARMS gave no result in seven samples (14%). Overall, there was a 73 to 100% concordance between the three methods. In this study, LiPA HIV-1 RT proved to be an accurate and reliable alternative to DNA sequencing for the detection of drug resistance mutations in patient samples.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705178     DOI: 10.1016/s0166-0934(98)00043-3

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs.

Authors:  S García-Bujalance; C Ladrón de Guevara; J González-García; J R Arribas; A Gutiérrez
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

2.  Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.

Authors:  J Servais; C Lambert; E Fontaine; J M Plesséria; I Robert; V Arendt; T Staub; F Schneider; R Hemmer; G Burtonboy; J C Schmit
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

3.  Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy.

Authors:  Jean Servais; Christine Lambert; Jean-Marc Plesséria; Elodie Fontaine; Isabelle Robert; Vic Arendt; Thérèse Staub; Robert Hemmer; François Schneider; Jean-Claude Schmit
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.

Authors:  Lisa M Frenkel; Yang Wang; Gerald H Learn; Jennifer L McKernan; Giovanina M Ellis; Kathleen M Mohan; Sarah E Holte; Shannon M De Vange; Diane M Pawluk; Ann J Melvin; Paul F Lewis; Laura M Heath; Ingrid A Beck; Madhumita Mahalanabis; Wilscott E Naugler; Nicole H Tobin; James I Mullins
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results.

Authors:  Klaus Korn; Heide Reil; Hauke Walter; Barbara Schmidt
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

6.  Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.

Authors:  Giovanina M Ellis; Madhumita Mahalanabis; Ingrid A Beck; Gregory Pepper; Amy Wright; Shannon Hamilton; Sarah Holte; Willscott E Naugler; Diane M Pawluk; Chung-Chen Li; Lisa M Frenkel
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 7.  Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

Authors:  A M Vandamme; K Van Laethem; E De Clercq
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.